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Abstract 
Purpose: To study the effect of conformal radiotherapy combined with epidermal growth factor 
receptor-tyrosine kinase inhibitor (EGFR-TKI) in the second-line treatment of non-small cell lung cancer 
(NSCLC). 
Methods: A total of 316 patients attending Shanghai Pulmonary Hospital affiliated to Tongji University, 
were divided into two groups: 106 patients were treated with conformal radiotherapy combined with 
EGFR-TKI (gefitinib, 250 mg/day; or erlotinib, 150 mg/day), while 210 patients were treated with EGFR-
TKI alone. Some factors, including adverse reactions (AR), disease control rate (DCR), progression-free 
survival (PFS), overall survival (OS), and one-year and two-year survival rate, were evaluated.  
Results: No obvious difference was observed in AR between the two groups (p > 0.05). In the 
combination therapy group, complete response (CR) was 5 cases, partial response (PR) 43 cases, and 
stable disease (SD) 47 cases, progressive disease (PD) was 11 cases, response rate (RR) was 45.3 %, 
and DCR 89.6 %. Median PFS in the combination therapy group and targeted therapy group was 6.5 
and 5.0 months, respectively. On the other hand, median OS in the combination therapy group and 
targeted group was 14.1 and 12.6 months, respectively.  One-year survival rate of the combination 
therapy group and EGFR-TKI group was 60.3 and 50.0 %, respectively, while the two-year survival rate 
was 26.3 and 19.0 %, respectively. 
Conclusion: Conformal radiotherapy combined with EGFR-TKI can be used as an effective second-line 
treatment for NSCLC. 
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Lung cancer is the primary cause of cancer 
deaths. In the last 30 years, the incidence of lung 
cancer in China has increased significantly, 
especially in females [1,2]. Non-small cell lung 
cancer (NSCLC) accounts for 80 – 85 % of lung 
cancers [3]. Clinically, more than two-thirds of 
NSCLC patients do not opt for radical surgery 
when definite diagnosis is made [4]. Currently, 
radio chemotherapy is the first choice of 
conventional treatment; however it is limited by 
poor efficacy and side effects [5-8]. Recently, 
epidermal growth factor receptor inhibitor 
(EGFR-TKI), a targeted therapy, has become a 
hotspot for treating NSCLC. Epidermal growth 
factor receptor (EGFR) is type I transmembrane 
tyrosine kinase receptor, a member of ErbB/HER 
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family. Studies have found that EGFR inhibitors 
can enhance the radiosensitivity of cancer cells 
[9,10]. 
 
Radiotherapy is the most powerful local 
treatment method besides surgery, while 
targeted therapy has an efficacy close to or even 
superior to chemotherapy, and the side effects 
are much fewer than chemotherapy. Currently, 
combination therapy has become a hot strategy 
for treating NSCLC. The role of EGFR-TKI in 
second-line treatment of NSCLC has generally 
been accepted, but the efficacy and influencing 
factors of radiotherapy combined with TKI as 
second-line treatment need further studies. This 
study investigates the clinical outcomes of 
conformal radiotherapy combined with EGFR-TKI 
(combination therapy) in the management of 






NSCLC patients attending Shanghai Pulmonary 
Hospital affiliated to Tongji University and on 
second- and third-line treatments from January 
2009, were divided into two groups. One group 
received EGFR-TKI combined with thoracic 
radiotherapy, while the second group received 
EGFR-TKI monotherapy. The patients were 
followed up for a period of 44 months. A total of 
316 cases entered the step of study analysis, 
and clinical data were collected from the patients 
at Shanghai Pulmonary Hospital affiliated to 
Tongji University. 
 
Inclusion criteria  
 
1. All the patients were diagnosed as NSCLS 
with definite pathological types; in addition, date 
study commenced, and pathological specimens 
(including surgical pathological tissues and 
sections, lung puncture or biopsy specimens, 
sputum basal cell detection, lymph node or other 
metastasis puncture or biopsy specimens, fiber 
optic bronchoscope biopsy or brush biopsy, or 
lavage fluid basal cell detection, etc).  
 
2. All the patients were diagnosed as NSCLS in 
stage III or IV, or had treatment failure with first- 
or second-line treatment (181 patients received 
EGFR-TKI therapy after first-line treatment failed, 
and 135 patients received EGFR-TKI therapy 
after second-line treatment failed.), and did not 
receive thoracic radiotherapy and EGFR-TKI 





The experimental protocols were approved by 
the Institutional Ethics Committee of Shanghai 
Pulmonary Hospital, Tongji University (approval 
no. K09-173), and all the patients enrolled were 
required to read and sign an informed consent 




The subjects were divided randomly into two 
groups: 106 patients were treated with conformal 
radiotherapy combined with EGFR-TKI (gefitinib, 
250 mg/day or erlotinib, 150 mg/day), tagged 
combination therapy group), while 210 patients 
were treated with EGFR-TKI alone (gefitinib, 250 
mg/day or erlotinib, 150 mg/day), i.e., EGFR-TKI 
monotherapy group.  
 
Thoracic radiotherapy protocol of the 
combination therapy group: spiral CT scanning 
was firstly performed (the scanning ranged from 
thoracic inlet to costophrenic angle, and layer 
thickness was 0.5 cm). The results were 
transmitted to the TPS planning system via 
internet. Thereafter, the target region was 
sketched and lymph nodes (lymph nodes > 1 cm) 
and lung primary tumor were enlarged and seen 
at the target regions (including mediastinum and 
hilus pulmonis). Based on the images, the gross 
tumor volume (GTV) and planning target volume 
(PTV) were sketched out, expanded PTV by 0.5 
~ 1.5 cm according to individual patient’s 
conditions, own breathing exercises, lesion 
location, position error and other factors, and 
then sketched out the basic structure of the 
threatened organs (commonly heart, esophagus, 
spinal cord, bilateral lung tissues, etc). Normal 
lung tissues were evaluated with the percentage 
of 20 Gy radiation volumes in the total lung 
volume (V20). All the combination therapy 
patients received conventional-dose conformal 
radiotherapy, 90 % of total PTV: 40.35 ~ 64.27 
Gy, 1.8 ~ 2 Gy/day, 5 times / week (Table 1). 
 
Table 1: Operating conditions for thoracic conformal 
radiotherapy 
 
Variable N Variable N 
Dose 106 Palliative 
radiotherapy 
58 
  40~50 Gy 18 Radical 
radiotherapy 
48 
  50~60 Gy 61 Lung V20  
    >60 Gy 27   ≤25 % 93 
  >25 % 13 
 
ADx-ARMS EGFR gene mutation detection kit 
(21 kinds) and ADx-ARMS KRAS gene mutation 
detection kit (7 kinds) (Amoy Diagnostics Co., 
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Ltd) were used detect EGFR and KRAS 
mutations respectively. 
 
Efficacy evaluation criteria used 
 
Short-term efficacy evaluation was based on 
chest computed tomography (CT) after 3 months 
of treatment. Response evaluation criteria for 
solid tumors (RECIST) were used for the 
evaluation. Efficacy included: complete response 
(CR), partial response (PR), stable disease (SD) 
and progressive disease (PD). Response rate 
(RR): CR + PR/total number of cases. Disease 
control rate (DCR): CR + PR + SD/total number 
of cases. 
 
Evaluation of long-term efficacy 
 
It included progression-free survival (PFS, time 
from start of treatment to tumor progression, last 
follow-up visit or death), the median overall 
survival (OS), and one-year and two-year 
survival rate. 
 
Evaluation of adverse reactions 
 
Drug reactions were evaluated according to the 
WHO anti-cancer drug side effects indexing 
standards, and radiotherapy reactions were 
evaluated according to the USA RTOG 
(Radiation Therapy Oncology Group) acute 




SPSS 13.0 software was used for Chi-squared 
test for univariate analysis, while Kaplan-Meier 
method was used to calculate survival rate. 
Verification was carried out using Logrank 
method. Logistic regression was used to analyze 
interstitial pneumonia-related factors, and Cox 
regression model was used for survival 
multivariate analysis. Statistical significance level 




A total of 316 entered the study, including 197 
males and 119 females, aged 32 - 79 years, with 
a median age of 63 years old (Table 1).  







  EGFR-TKI mono-
therapy group 
(n=210) 
χ 2 P-value 
Age       1.204 0.273 
  ≤70 27  66    
  >70 79 144    
Gender   1.562 0.211 
  Male 61 136    
  Female 45  74    
ECOG score   0.904 0.636 
  0 11  22    
  1 67 122    
  2 28  66    
Smoking history   1.076 0.300 
  >300 year cigarettes 51 114    
  ≤300 year cigarettes 55 96    
Position of primary lesion      
  Upper lobe 24 58   
  Median lobe and lower lobe 82 152 0.908 0.341 
TNM staging       
  IIIA 23 59     
  IIIB 40  89     
  IV 43  62     
Pathological type   4.068 0.131 
  Squamous carcinoma 30  57     
  Adenocarcinoma 55 118     
  Adenosquamous carcinoma  8 13     
  Large cell carcinoma  9  15 0.675 0.954 
  Unspecified types  4 7   
ECOG = Eastern Cooperative Oncology Group; TNM staging = TNM Classification of Malignant Tumours staging 
system 
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and the median lung V20 was 21 % (9 - 29 %). 
The length of esophagus receiving 45 Gy and 55 
Gy radiation were 8.1 cm (0 ~ 17.2 cm) and 4.7 
cm (0 - 15.3 cm), respectively. 
 
The results of the texts done on the specimens 
showed that EGFR mutation rate in 
adenocarcinoma was about 45.2 %, the total 
EGFR mutation rate was about 30.1 %, KRAS 
mutation rate was about 10.1 %, and only three 
patients developed both EGFR and KRAS 
mutations (Table 3). 
 
In our present study, no obvious difference was 
observed for the adverse reaction (AR) between 
the two groups (p > 0.05) (Table 4). For 
interstitial pneumonia, logistic regression 
analysis showed that smoking and V20 were 
related to the occurrence of interstitial 
pneumonia (Table 5). 
 
Table 3: Gene test results 
 
Gene test N 
  EGFR mutation 
  KRAS mutation 
  Double mutations 






In the combination therapy group, CR was in 5 
cases, PR in 43 cases, SD in 47 cases, PD in 11 
cases, RR 45.3 %, and DCR 89.6 %; in the 
targeted therapy group, CR was in 7 cases, PR 
in 45 cases, SD in 84 cases, PD in 74 cases, RR 
24.8 % and DCR 64.8 %, and the differences in 
RR and DCR were statistically significant (Table 
6). 
 
In the combination therapy group, median PFS 
was 6.5 months and the median OS was 14.1 
months; in the targeted therapy group, the 
median PFS was 5.0 months and the median OS 
was 12.6 months. In the combination therapy 
group, the one-year survival rate was 60.3 % and 
the two-year survival rate was 26.3 %; in the 
targeted therapy group, the one-year survival 
rate was 50 % and the two-year survival rate was 
19 %: PFS (χ2 = 3.706, p = 0.054), OS (χ2 = 
3.308, p = 0.069) (Fig 1). 
 
In the combination therapy group, KRAS 
mutation and TNM staging correlated with 
survival, as risk factors, while EGFR mutation 
correlated with survival, as a protective factor. In 
patients with EGFR mutation, the median PFS 
was 9.7 months and the median OS was 16.3 
months; in the patients with KRAS mutation, the 
median PFS was 2.6 months and the median OS 
was 6.3 months (Table 7). 
 









χ 2 P-value 
Rash G1-2 55 (51.9 %) 107 (60.0 %) 0.025 0.875 
Peeling 16 (15.1 %) 29 (13.8 %) 0.095 0.758 
Oral ulcer 11 (10.4 %) 19 (9.0 %) 0.145 0.703 
Interstitial pneumonia G1-2 16 (15.1 %) 21 (10 %) 1.768 0.184 
Esophagitis G1-3 43 (40.6 %) 25 (11.9 %) 34.264 < 0.001 
Nausea and vomiting 11 (10.4 %) 19 (9.0 %) 0.145 0.703 
Diarrhea 8 (7.5 %) 22 (10.5 %) 0.703 0.402 
Granulopenia 12 (11.3 %) 18 (8.6 %) 0.620 0.431 
Reduced hemachrome 15 (14.2 %) 23 (11.0 %) 0.681 0.409 
 
         Table 5: Interstitial pneumonia-related risk factors 
 
Variable Β χ 2 P-value OR 95 % CI 
Smoking 0.254 4.119 0.0424 1.29 1.02-3.21 
V20 0.168 7.291 0.0069 1.18 1.07-2.29 
 
   Table 6: Short-term efficacy in the two groups 
 
Variable    Second-line combination group 
Second-line 
targeting group χ 
2 P-value 
RR 45.3 % 24.8 % 13.714 0.000 
DCR 89.6 % 64.8 % 22.142 0.000 
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        Table 7: Prognosis multivariate analysis by Cox method for combination therapy 
 
Variable β χ 2    p    HR    95 CI     
KRAS 0.288 6.70 0.030 1.33 1.21-3.36 
TNM staging 0.453 18.00 0.000 1.54 1.34-5.52 
EGFR -0.403 4.87 0.0027 0.67 0.33-0.85 
 
 




Thoracic radiotherapy has been considered the 
most effective method for the treatment of 
primary tumor besides surgery. Conformal 
radiotherapy has become a standard 
radiotherapy for lung radiotherapy [13-15]. 
Additionally, radiotherapy can significantly 
reduce side effects of radiotherapy. However, 
radiotherapy is a topical treatment method. The 
major lung cancer has been in locally advanced 
when detected clinically. For these patients in 
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middle and advanced stages, the efficacy of 
radiotherapy is limited, and it must be combined 
with drugs to achieve the treatment goals [11-
15]. 
 
Molecular targeted therapy, as the greatest 
development in NSCLC treatment method, has 
been widely used clinically, and EGFR-TKI has 
become a hotspot in this field. The effects of 
EGFR-TKI as a basic drug in second-line 
treatment of NSCLC have obtained a consensus, 
and the National Comprehensive Cancer 
Network (NCCN) has also recommended EGFR-
TKI as a first-line drug for patients with EGFR 
mutations [16]. Meanwhile, the efficacy of 
synchronous radiotherapy and chemotherapy in 
treatment of NSCLC is superior to that of 
sequential radiotherapy and chemotherapy [17]. 
However, the side effects of synchronous 
treatment have increased significantly. 
Compared with chemotherapy drugs, EGFR-TKI 
has significantly less side effects and can even 
be used for patients with PS > 2 points. The most 
obvious adverse reaction of thoracic radiotherapy 
is radiation pneumonitis. Interstitial pneumonia 
could be induced by both the radioactive rays 
and EGFR-TKI. Thus, for synchronous treatment, 
lung is the common target of lethal side effects, 
and the incidence of interstitial pneumonia 
increases significantly. In clinical trials CALGB 
30106 and SWOG 9504, EGFR-TKI was 
combined with thoracic radiotherapy, and serious 
lung toxic reactions did not occur in the radiation 
field, suggesting that EGFR-TKI combined with 
thoracic radiotherapy is safe and feasible [18,19]. 
As the two most common methods for EGFR and 
KRAS gene detection, direct DNA sequencing 
method and real-time PCR technology-based 
ARMS method have their own characteristics. 
The sequencing method is currently the gold 
standard for detection and can detect known and 
unknown EGFR mutations, and ARMS method 
can detect small amounts of cells and has higher 
sensitivity. Our experiment mainly aimed at 
sensitive EGFR mutations and determination of 
short and long-term efficacy of radiotherapy, 
sensitive mutations were known mutations 
concentrated on nos. 19 and 21 loci, and the 
mutation types were known, so we chose the 
high-sensitivity ARMS method for detection. 
 
The results of the present study showed that as a 
main prognostic factor for EGFR efficacy 
evaluation, the detection rate of EGFR mutations 
during the whole treatment was very low, and 
only less than 10 % of the patients underwent 
genetic testing for EGFR. This might be due to 
high financial cost of such test in the study site 
and also due to low level of medical insurance by 
the patients which might be related to the testing 
expense of more than two thousand yuan and no 
medical insurance.  
 
By testing the pathological specimens collected 
by the pathology department, this investigation 
found that EGFR mutation rate for 
adenocarcinoma (45.2 %) was significantly 
higher than other types of NSCL. The EGFR 
mutation rate in female, non-smoking and 
adenocarcinoma patients was 82.7 %. KRAS 
mutation rate was about 10.1 %, far below the 
mutation rate of nearly 30 % earlier reported in 
western countries, supporting the fact that the 
EGFR mutation rate in eastern countries was 
high, while the KRAS mutation rate in western 
countries was high [20,21]. The KRAS mutation 
rate in patients with smoking > 300 year 
cigarettes reached 16.4 %, suggesting that 
KRAS mutations are correlated with smoking. 
Only 3 cases developed both EGFR and KRAS 
mutations, indicating that EGFR genes and 
KRAS genes are mutually exclusive.  
 
Our results revealed that proportion of males was 
higher than females by nearly 25 %, and nearly 
30 % of the patients with ECOG PS score = 2 
points received two and three-line treatment, 
suggesting that after recurrence or metastasis 
after chemotherapy, the patients’ PS score 
decreased significantly. In all cases, the cases in 
IV stage accounted for 33.2 %, and the rest were 
cases in IIIA and IIIB stages, suggesting that 
after chemotherapy failed, the patients’ stages 
increased significantly. In all the cases, the 
proportion of adenocarcinoma was significantly 
higher than other types of NSCLC. In first and 
second-line chemotherapy, the protocol was 
generally changed after 2 - 4 cycles of 
chemotherapy failed. The two groups received 
thoracic radiotherapy combined with EGFR-TKI 
therapy and EGFR-TKI monotherapy 
respectively, and the differences in age, gender, 
ECOG score, stages, pathological types and 
EGFR and KRAS mutations between the two 
groups were not statistically different.  
 
All cases received EGFR-TKI therapy after 
progression, including erlotinib in 163 cases and 
gefitinib in 153 cases, and the selection of 
targeting drugs was not specific. 106 patients 
received EGFR-TKI therapy combined with 
thoracic radiotherapy. Only 48 patients received 
radical radiotherapy due to early stages, and 58 
patients received palliative radiotherapy. NCCN 
did not recommend thoracic radiotherapy for 
stage IV patients, so the number of stage IV 
cases receiving thoracic radiotherapy was 
limited, but many studies found that thoracic 
radiotherapy for stage IV patients could improve 
local efficacy and long-term survival to a certain 
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extent. We chose V20 as the main evaluation 
indicator for lung radiotherapy reactions and 
found that the patients with V20 below 25 % 
accounted for 87.7 %, and the requirements in 
these plans made the incidence of radiation 
pneumonitis within an acceptable range. 
 
After treatment, the hematologic toxicity, 
gastrointestinal reactions, rash and mucosa 
reactions in the two groups were almost similar; 
however incidence of esophagitis and interstitial 
pneumonia in combination therapy group 
increased, which were not seen in the targeted 
therapy group, and except esophagitis. Lungs 
were the common target point of radiotherapy 
and EGFR-TKI therapy, and results showed that 
the key points for lower incidence of interstitial 
pneumonia in the combination therapy group 
were lung V20 and smoking status, and in the 
patients with V20 less than 20 % and smoking 
index lower than 300 year cigarettes, the 
incidence of radiation pneumonitis rate fell below 
10 %, and only grade 1 radiation pneumonitis 
occurred, suggesting that no smoking or less 
smoking and V20 < 20 % is the safety margin for 
combination therapy. 
 
In the combination therapy group, RR was 45.3 
% and DCR was 89.6 %, significantly higher than 
24.8 % and 64.8 % in the targeted therapy group, 
and the differences were statistically significant, 
showing the advantages of radiotherapy in local 
treatment. So far, in addition to surgery, 
radiotherapy is still the most effective local 
treatment method. When combined with EGFR-
TKI therapy, radiotherapy plays a synergistic 
treatment role and is significantly superior to 
short-term efficacy of targeted therapy. 
 
The median PFS in combination therapy group 
was 6.5 months, 1.5 months more than that in 
targeted therapy group; the median OS in 
combination therapy group was 14.1 months, 1.5 
months more than that in targeted therapy group. 
No obvious differences in PFS and OS was 
observed between the two groups, however, 
when combined with thoracic radiotherapy, PFS 
and OS were slightly increased in the 
combination therapy group. Previous 
investigation suggested that synchronous 
chemotherapy combined with erlotinib 
maintenance therapy is an effective and well 
tolerated method in treatment of unresectable 
stage III NSCLC. All patients in the reported 
study were Caucasians, smoking and 
complicated by squamous carcinoma, but the 
median erlotinib maintenance still reached 18.7 
months [22]. In our study, the median OS in the 
combination therapy group was 14.1 months, 
appearing as promising survival due to many of 
them were in stage IV. 
 
In the cases receiving EGFR-TKI therapy 
combined with thoracic radiotherapy, EGFR 
mutations, KRAS mutations and tumor stages 
were associated with survival, EGFR was a 
radiation-sensitizing factor, the short-term 
efficacy on EGFR mutations reached 70 - 80 %, 
and PFS of patients with EGFR mutations was 
more than that in patients without mutations. In 
cases of EGFR mutations, the median PFS was 
9.7 months and the median OS was 16.3 
months, and PFS and OS of patients with EGFR 
mutations were more than those of patients 
receiving combination therapy. Mutations of 
KRAS genes encoding EGFR downstream 
GTPase was the main reason for drug resistance 
in NSCLC patients, and in the cases receiving 
combination therapy, patients with KRAS 
mutations had the median PFS of 2.6 months 
and the median OS of 6.3 months. PFS and OS 
were significantly less than those in the whole 
combination therapy group, suggesting that 
KRAS mutation was the reason for EGFR-TKI 
resistance and also a factor for radiotherapy 
resistance.  
 
Limitations of the study 
 
Not all the patients in the targeted therapy group 
treated with EGFR-TKI were selected by gene 
determination. Therefore, some of the patients 
were not sensitized to TKI treatment, which will 




Collectively, the findings of this study 
demonstrate that conformal radiotherapy 
combined with EGFR-TKI can be used as an 
effective strategy in the second-line treatment of 
NSCLC. 
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